With the start of Asco just around the corner a review of EP Vantage’s cancer coverage from the last six months reveals that a number of tumour types including liver and pancreatic could see critical data emerge this year.
Meanwhile data on mechanisms like Parp inhibition and CAR-T therapies are also keenly awaited, for clues as to their real potential.
The articles gathered here highlight recent breakthroughs and setbacks and flag the approaching data points.
Ovarian cancer – the field readies itself for phase III readouts
Pancreatic cancer – this time it’s (getting) personal
Parp inhibitors – set to come of age in 2016
CAR-T – how do you solve a problem like relapse?
